Cohance infuses USD 10 million into subsidiary NJ Bio via CCPS

Strategic Transactions View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹436.40

prior close

₹438.45

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.0%+5.0% vs market

Pharmaceuticals peers, median of 174sector+0.2%+4.8% vs sector

On the reaction day the stock moved 5.0 pts more than Nifty Smallcap 250 and 4.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.1

15m

+0.6

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0-0.0+5.0+0.2+4.8

Next day

+3.8-0.1+3.9+0.1+3.7

+5.9+0.7+5.3+1.0+4.9

+4.0-0.7+4.7-0.1+4.0

+5.1-0.7+5.8+0.0+5.1

+4.1-2.3+6.4-0.5+4.6

+1.6-2.7+4.3-1.0+2.6

15d

-0.1-2.5+2.4-4.5+4.5

+5.7-6.8+12.6-7.4+13.1

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences has invested USD 10 million in its subsidiary NJ Bio Inc., USA by subscribing to 188,680 Compulsorily Convertible Preferred Shares (CCPS) at USD 53 per share, funded through internal accruals. NJ Bio is an ADC-focused CRDMO with turnover of USD 20.6 million (CY2023), USD 32.6 million (CY2024), and USD 23.5 million (CY2025). The CCPS are convertible to equity after 3 years. The transaction follows the board approval from December 2025 and is expected to complete by end of September 2026.

Likely market impact

Reinforces Cohance's commitment to the high-growth ADC CRDMO space, supports NJ Bio's growth and capex, funded internally with no equity dilution.